Press Release
Global Depression Drugs Market is Expected to Reach $18 Billion, by 2024, Says Variant Market Research
 Published Date:  Feb 2017  Publish By: Variant Market Research

Global Depression Drug Market published by Variant Market Research is expected to reach $18 billion by 2024 from $15 billion in 2016; growing at a CAGR of 2.6% from 2016 to 2024. By geography, Asia-Pacific and Europe are expected to grow at a CAGR of 3.2% and 2.7%, respectively, during the forecast period.

"Depression Drugs Market (By Type: Tricyclice Antidepressants, Serotonin-Norepinephrine Inhibitors, Atypical Antipsychotics, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Tetracyclic Antidepressants, Monoamine Oxidase Inhibitors, Others; By Application: Clinics and Hospitals, Research Centers; By Geography: North America, Europe, Asia Pacific, RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024"

To browse the complete report, visit at https://www.variantmarketresearch.com/report-categories/pharmaceuticals/depression-drugs-market

Growth in geriatric population, rising efficacy and declining side effects of drugs are the major factors driving the global depression drug market.  However, lack of awareness among individuals regarding depression and its rising prevalence would limit the demand for depression drugs in coming years. Augmenting prevalence of fretfulness and various other depression disorders would provide several growth opportunities for the market in coming years.

People moving from rural to urban areas and their suddenly changing lifestyle is one of the major factors driving the growth of depression drug market globally. People move from rural to urban areas and sudden changes take place in their life in terms of job, the standard of living, dressing, and lifestyle among others. They find it difficult to match with the lifestyle of the people living in urban areas which leads to depression among them. These cases are found majorly among women primarily in developing countries. Growing geriatric population and rise in the number of generic drug market are some of the other factors driving the growth of depression drug market.

The global depression drug market is majorly classified as anticonvulsants, serotonin-norepinephrine reuptake inhibitors (SNRIs), beta-blockers, benzodiazepines, tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs). Among all the segments, SNRIs dominated the market accounting for more than one-fourth of the total depression drugs market share in 2016. Geographically, the market is categorized into North America, Europe, Asia-Pacific and Rest of the world.

North America accounted for the largest market share of 37.2% in 2016; owing to the presence of large consumer base suffering from various kinds of depression and fretfulness disorders. Europe was the second largest market with a total market share of 32.6%. In terms of growth, Asia-Pacific is to attain the fastest CAGR of 3.2% during the forecast period, driven by increased demand from emerging countries such as China, Japan, and Australia. Rising awareness among consumers regarding benefits of depression drug is also expected to propel the growth of depression drugs market in the region.

Market players have used various strategies to increase consumer awareness and gain their market presence. The major players in the market include H. Lundbeck, Merck & Co., SK Biopharmaceuticals, Novartis, AstraZeneca, Forest Laboratories, Naurex, GlaxoSmithKline, Eli Lilly and Co., Naurex, and others.

Contact Us:
John Dave,
Head - Sales
Variant Market Research
649 Mission St, 5th Floor, San Francisco,
CA 94105,United States.
Tel: +1-415-680-2785
Fax: +1-415-680-2786
Email: john.dave@variantmarketresearch.com
Email: help@variantmarketresearch.com


GET MORE INFORMATION ABOUT THIS REPORT


Refresh Captcha

Chapter 1 Prefix
    1.1 Market Scope
    1.2 Report Description
    1.3 Research Methodology
          1.3.1 Primary Research
          1.3.2 Secondary Research
          1.3.3 In-house Data Modeling
Chapter 2 Executive Summary
Chapter 3 Market Outline
    3.1 Market Inclination, Trend, Outlook and Viewpoint
    3.2 Market Share Analysis: Company’s Competitive Scenario
    3.3 Market Dynamics
          3.3.1 Drivers
                   3.3.1.1 Impact Analysis
          3.3.2 Restraints
                   3.3.2.1 Impact Analysis
          3.3.3 Opportunities
Chapter 4 Depression Drug Market by Type: Market Size and Forecast, 2015 – 2024
    4.1 Overview
    4.2 Anticonvulsants
          4.2.1 Current Trend and Analysis
          4.2.2 Market Size and Forecast
    4.3 Serotonin-norepinephrine reuptake inhibitors (SNRIs)
          4.3.1 Current Trend and Analysis
          4.3.2 Market Size and Forecast
    4.4 Beta-blockers
          4.4.1 Current Trend and Analysis
          4.4.2 Market Size and Forecast
    4.5 Benzodiazepines
          4.5.1 Current Trend and Analysis
          4.5.2 Market Size and Forecast
    4.6 Tetracyclic antidepressants (TeCAs)
          4.6.1 Current Trend and Analysis
          4.6.2 Market Size and Forecast
    4.7 Selective serotonin reuptake inhibitors (SSRIs)
          4.7.1 Current Trend and Analysis
          4.7.2 Market Size and Forecast
    4.8 Monoamine oxidase inhibitors (MAOIs)
          4.8.1 Current Trend and Analysis
          4.8.2 Market Size and Forecast
Chapter 5 Depression Drug Market by Application: Market Size and Forecast, 2015 – 2024
    5.1 Overview
    5.2 Clinics and Hospitals
          5.2.1 Current Trend and Analysis
          5.2.2 Market Size and Forecast
    5.3 Research Centers
          5.3.1 Current Trend and Analysis
          5.3.2 Market Size and Forecast
Chapter 6 Depression Drug Market by Geography: Market Size and Forecast, 2015 – 2024
    6.1 Overview
    6.2 North America
          6.2.1 Current Trend and Analysis
          6.2.2 Market Size and Forecast
          6.2.3 US
                   6.2.3.1 Market Size and Forecast
          6.2.4 Canada
                   6.2.4.1 Market Size and Forecast
          6.2.5 Mexico
                   6.2.5.1 Market Size and Forecast
    6.3 Europe
          6.3.1 Current Trend and Analysis
          6.3.2 Market Size and Forecast
          6.3.3 Germany
                   6.3.3.1 Market Size and Forecast
          6.3.4 France
                   6.3.4.1 Market Size and Forecast
          6.3.5 United Kingdom
                   6.3.5.1 Market Size and Forecast
          6.3.6 Rest of Europe
                   6.3.6.1 Market Size and Forecast
    6.4 Asia-Pacific
          6.4.1 Current Trend and Analysis
          6.4.2 Market Size and Forecast
          6.4.3 China
                   6.4.3.1 Market Size and Forecast
          6.4.4 India
                   6.4.4.1 Market Size and Forecast
          6.4.5 Japan
                   6.4.5.1 Market Size and Forecast
          6.4.6 Australia
                   6.4.6.1 Market Size and Forecast
          6.4.7 Rest of Asia-Pacific
                   6.4.7.1 Market Size and Forecast
    6.5 RoW
          6.5.1 Current Trend and Analysis
          6.5.2 Market Size and Forecast
          6.5.3 The Middle East
                   6.5.3.1 Market Size and Forecast
          6.5.4 South America
                   6.5.4.1 Market Size and Forecast
          6.5.5 Africa
                   6.5.5.1 Market Size and Forecast
Chapter 7 Company Profiles
    7.1 H.Lundbeck, Merck & Co.
    7.2 SK Biopharmaceuticals
    7.3 Novartis
    7.4 AstraZeneca.
    7.5 Forest Laboratories
    7.6 Naurex
    7.7 GlaxoSmithKline
    7.8  Eli Lilly and Co.
List of Figures
FIG. 1 MARKET SEGMENTATION: GLOBAL DEPRESSION DRUGS MARKET
FIG. 2 MARKET SHARE ANALYSIS, 2016 (%)
FIG. 3 GLOBAL DEPRESSION DRUGS MARKET SHARE AND FORECAST, BY TYPE 2016 Vs 2024 (VALUE %)
FIG. 4 TRICYCLICE ANTIDEPRESSANTS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 5 SEROTONIN-NOREPINEPHRINE INHIBITORS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 6 ATYPICAL ANTIPSYCHOTICS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 8 BENZODIAZEPINES MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 9 TETRACYCLIC ANTIDEPRESSANTS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 10 MONOAMINE OXIDASE INHIBITORS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 11 OTHER PRODUCT TYPE MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 12 GLOBAL DEPRESSION DRUGS MARKET SHARE AND FORECAST, BY INDUSRTY VERTICAL, 2016 VS. 2024 (VALUE %)
FIG. 13 CLINICS AND HOSPITALS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 14 RESEARCH CENTRES MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 15 GLOBAL DEPRESSION DRUGS MARKET SIZE AND FORECAST BY GEOGRAPHY, 2016 Vs 2024 (REVENUE, CAGR %)
FIG. 16 NORTH AMERICA DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 17 NORTH AMERICA DEPRESSION DRUGS MARKET SIZE AND FORECAST BY COUNTRY, 2015 – 2024 ($ BILLION)
FIG. 18 U.S. DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 19 CANADA DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 20 MEXICO DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 21 EUROPE DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 BY COUNTRY, ($ BILLION)
FIG. 22 U.K. DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 23 FRANCE DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 24 GERMANY DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 25 OTHERS DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 26 ASIA-PACIFIC DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 BY COUNTRY ($ BILLION)
FIG. 27 CHINA DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 28 INDIA DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 29 JAPAN DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 30 OTHERS DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 31 REST OF THE WORLD DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 BY COUNTRY ($ BILLION)
FIG. 32 SOUTH AMERICA DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 33 MIDDLE EAST DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
FIG. 34 AFRICA DEPRESSION DRUGS MARKET SIZE AND FORECAST, 2015 – 2024 ($ BILLION)
List of Tables
TABLE 1 GLOBAL DEPRESSION DRUGS MARKET SNAPSHOT
TABLE 2 GLOBAL DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY REGION, 2015 – 2024 ($ BILLION)
TABLE 3 DRIVER OF THE GLOBAL DEPRESSION DRUGS MARKET: IMPACT ANALYSIS
TABLE 4 RESTRAINTS OF THE GLOBAL DEPRESSION DRUGS MARKET: IMPACT ANALYSIS
TABLE 5 TRICYCLICE ANTIDEPRESSANTS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 6 SEROTONIN-NOREPINEPHRINE INHIBITORS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 7 ATYPICAL ANTIPSYCHOTICS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 8 SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 9 BENZODIAZEPINES MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 10 TETRACYCLIC ANTIDEPRESSANTS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 11 MONOAMINE OXIDASE INHIBITORS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 12 OTHER PRODUCT TYPE MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 13 CLINICS AND HOSPITALS MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 14 RESEARCH CENTRES MARKET SIZE AND FORECAST, BY REGIONS, 2015 – 2024 ($ BILLION)
TABLE 15 NORTH AMERICA DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY PRODUCT TYPE, 2015 – 2024 ($ BILLION)
TABLE 16 NORTH AMERICA DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY APPLICATION, 2015 – 2024 ($ BILLION)
TABLE 17 EUROPE DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY PRODUCT TYPE, 2015 – 2024 ($ BILLION)
TABLE 18 EUROPE DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY APPLICATION, 2015 – 2024 ($ BILLION)
TABLE 19 ASIA-PACIFIC DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY PRODUCT TYPE, 2015 – 2024 ($ BILLION)
TABLE 20 ASIA-PACIFIC DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY APPLICATION, 2015 – 2024 ($ BILLION)
TABLE 21 REST OF THE WORLD DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY PRODUCT TYPE, 2015 – 2024 ($ BILLION)
TABLE 22 REST OF THE WORLD DEPRESSION DRUGS MARKET SIZE AND FORECAST, BY APPLICATION, 2015 – 2024 ($ BILLION)
TABLE 23 GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 24 H. LUNDBECK: COMPANY SNAPSHOT
TABLE 25 SK BIOPHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 26 NOVARTIS: COMPANY SNAPSHOT
TABLE 27 ASTRAZENECA: COMPANY SNAPSHOT
TABLE 28 FOREST LABORATORIES: COMPANY SNAPSHOT
TABLE 29 NAUREX: COMPANY SNAPSHOT
TABLE 30 ELI LILLY AND CO.: COMPANY SNAPSHOT
TABLE 31 MERCK & CO.: COMPANY SNAPSHOT
TABLE 32 PFIZER INC.: COMPANY SNAPSHOT

GET MORE INFORMATION ABOUT THIS REPORT


Refresh Captcha

Please fill the form below and our research expert will get in touch with you.


Refresh Captcha

Please fill the form below and our research expert will get in touch with you.


Refresh Captcha